Chichester Jessica A, Haaheim Lars R, Yusibov Vidadi
Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 19711, USA.
Expert Rev Vaccines. 2009 Apr;8(4):493-8. doi: 10.1586/erv.09.3.
The reappearance of highly pathogenic avian influenza H5N1 in poultry in 2003, and the subsequent high-fatality zoonoses in Asia, Europe and Africa, has heightened the awareness of a potential pandemic and the need for global vaccine supply. Most manufacturers still use embryonated hens' eggs to produce influenza vaccines, a system that has demonstrated its value throughout six decades. There are, however, some challenges with this approach, both for seasonal and particularly for pandemic vaccine production. This review highlights some of these challenges and describes emerging alternative production platforms with the potential to deliver safe and effective vaccines to the global market in a timely fashion. A particular emphasis of this review will be on the production of recombinant influenza vaccines using transient plant expression systems.
2003年高致病性禽流感H5N1在家禽中再度出现，随后在亚洲、欧洲和非洲出现高致死率的人畜共患病，这提高了人们对潜在大流行的认识以及对全球疫苗供应的需求。大多数制造商仍使用受精鸡蛋来生产流感疫苗，这一体系在过去60年里已证明了其价值。然而，这种方法存在一些挑战，无论是对于季节性疫苗还是特别是大流行疫苗的生产。本综述强调了其中一些挑战，并描述了新兴的替代生产平台，这些平台有潜力及时向全球市场提供安全有效的疫苗。本综述将特别强调使用瞬时植物表达系统生产重组流感疫苗。
